The Nasal Polyps (Nasal Polyposis) drugs in development market research report provides comprehensive information on the therapeutics under development for Nasal Polyps (Nasal Polyposis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Nasal Polyps (Nasal Polyposis). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Nasal Polyps (Nasal Polyposis) and features dormant and discontinued products.
GlobalData tracks 11 drugs in development for Nasal Polyps (Nasal Polyposis) by 12 companies/universities/institutes. The top development phase for Nasal Polyps (Nasal Polyposis) is phase iii with four drugs in that stage. The Nasal Polyps (Nasal Polyposis) pipeline has 11 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Nasal Polyps (Nasal Polyposis) pipeline products market are: Maruho, F. Hoffmann-La Roche and AstraZeneca.
The key targets in the Nasal Polyps (Nasal Polyposis) pipeline products market include Immunoglobulin E, Glucocorticoid Receptor, and Histamine H1 Receptor.
The key mechanisms of action in the Nasal Polyps (Nasal Polyposis) pipeline product include Immunoglobulin E Inhibitor with three drugs in Pre-Registration. The Nasal Polyps (Nasal Polyposis) pipeline products include six routes of administration with the top ROA being Subcutaneous and two key molecule types in the Nasal Polyps (Nasal Polyposis) pipeline products market including Monoclonal Antibody, and Small Molecule.
Nasal Polyps (Nasal Polyposis) overview
Nasal polyps (nasal polyposis) is an inflammatory condition where non-cancerous growths develop in the nasal lining of nose. Signs and symptoms include runny nose, postnasal drip, headache, snoring, and loss of sense of taste. Risk factors include asthma, aspirin sensitivity, cystic fibrosis, Churg-strauss syndrome, and allergic fungal sinusitis. Treatment includes steroid medications.
For a complete picture of Nasal Polyps (Nasal Polyposis)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
